<p>Private Brazilian clinics plan to buy 5 million doses of a Covid-19 vaccine developed by Bharat Biotech, their association said on Monday in a statement.</p>.<p>Bharat Biotech has not yet applied for approval by Brazil's health regulator Anvisa for its Covaxin vaccine.</p>.<p>Geraldo Barbosa, head of the Brazilian Association of Vaccine Clinics (ABCVAC) who will lead a delegation to India departing on Monday, said a memorandum of understanding has already been signed with Bharat Biotech.</p>.<p>"This should be the first vaccine available on the private market in Brazil," he said.</p>.<p>The plan is for the 5 million doses of Covaxin to arrive in Brazil in mid-March, to be sold by private clinics.</p>.<p>Anvisa said in a statement on Sunday that Covaxin does not fit the continuous data submission process for vaccine registration and the vaccine would have to undergo clinical trial in Brazil.</p>.<p>Bharat Biotech, based in Hyderabad, produces millions of doses of vaccines for hepatitis, Zika, Japanese encephalitis and other illnesses.</p>.<p>In November, Bharat Biotech executives visited Brazil and offered the vaccine and a possible technology transfer partnership.</p>.<p>Covaxin is a whole-virion inactivated vaccine that could be licensed by the second quarter of 2021 in India, an executive told Reuters</p>
<p>Private Brazilian clinics plan to buy 5 million doses of a Covid-19 vaccine developed by Bharat Biotech, their association said on Monday in a statement.</p>.<p>Bharat Biotech has not yet applied for approval by Brazil's health regulator Anvisa for its Covaxin vaccine.</p>.<p>Geraldo Barbosa, head of the Brazilian Association of Vaccine Clinics (ABCVAC) who will lead a delegation to India departing on Monday, said a memorandum of understanding has already been signed with Bharat Biotech.</p>.<p>"This should be the first vaccine available on the private market in Brazil," he said.</p>.<p>The plan is for the 5 million doses of Covaxin to arrive in Brazil in mid-March, to be sold by private clinics.</p>.<p>Anvisa said in a statement on Sunday that Covaxin does not fit the continuous data submission process for vaccine registration and the vaccine would have to undergo clinical trial in Brazil.</p>.<p>Bharat Biotech, based in Hyderabad, produces millions of doses of vaccines for hepatitis, Zika, Japanese encephalitis and other illnesses.</p>.<p>In November, Bharat Biotech executives visited Brazil and offered the vaccine and a possible technology transfer partnership.</p>.<p>Covaxin is a whole-virion inactivated vaccine that could be licensed by the second quarter of 2021 in India, an executive told Reuters</p>